Clinical association between thyroid disease and immune thrombocytopenia

Immune thrombocytopenia (ITP) can coexist with autoimmune thyroid disease. However, the detailed clinical features remain unknown. We retrospectively reviewed 248 patients with newly diagnosed ITP in our institute for whom we had thyroid function data at diagnosis between 2000 and 2019. Of the 248 p...

Full description

Saved in:
Bibliographic Details
Published inAnnals of hematology Vol. 100; no. 2; pp. 345 - 352
Main Authors Ito, Shoko, Fujiwara, Shin-ichiro, Murahashi, Rui, Nakashima, Hirotomo, Matsuoka, Sae, Ikeda, Takashi, Kawaguchi, Shin-ichiro, Toda, Yumiko, Ban, Tetsuaki, Nagayama, Takashi, Umino, Kento, Minakata, Daisuke, Morita, Kaoru, Nakano, Hirofumi, Yamasaki, Ryoko, Ashizawa, Masahiro, Yamamoto, Chihiro, Hatano, Kaoru, Sato, Kazuya, Oh, Iekuni, Ohmine, Ken, Kanda, Yoshinobu
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Springer Berlin Heidelberg 01.02.2021
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Immune thrombocytopenia (ITP) can coexist with autoimmune thyroid disease. However, the detailed clinical features remain unknown. We retrospectively reviewed 248 patients with newly diagnosed ITP in our institute for whom we had thyroid function data at diagnosis between 2000 and 2019. Of the 248 patients with ITP, 74 patients also had thyroid disease, including 36 with overt thyroid disease (13 Graves’ disease and 23 Hashimoto’s thyroiditis) and 38 with subclinical thyroid disease (3 hyperthyroidism and 35 hypothyroidism). ITP and thyroid disease were concurrently diagnosed in 54 patients. Female sex and positivity for antinuclear antibodies (ANA) were significantly associated with thyroid diseases. Platelet-associated immunoglobulin G (PAIgG) levels in patients with Graves’ disease were higher than those in patients with Hashimoto’s thyroiditis. Platelet counts were similar among euthyroid patients and patients with thyroid disease. Thrombopoietin-receptor agonist was administered more frequently in patients with thyroid disease. The cumulative incidences of thrombosis and bleeding and overall survival did not differ between patients with and without thyroid disease. Treatment for thyroid disease in 22 patients improved thrombocytopenia in 21 patients, especially in 4 patients who were not treated for ITP. This study demonstrated that thyroid diseases were commonly found in patients with ITP. Treatment of the underlying thyroid disease may improve thrombocytopenia.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0939-5555
1432-0584
DOI:10.1007/s00277-020-04343-5